How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1065-1067
DOI: 10.1200/jco-25-03105 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von M Raheel Khan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Trinity St James's Cancer Institute, Trinity College, Dublin, Ireland. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Trinity St James's Cancer Institute, Trinity College, Dublin, Ireland.
ORCID-Profile: M Raheel Khan, Patrick M Forde
Zitieren
APA
Khan, M. R., & Forde, P. M. (2026). How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability. Journal of Clinical Oncology, 44(12), 1065-1067. https://doi.org/10.1200/jco-25-03105
Vancouver
Khan MR, Forde PM. How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability. Journal of Clinical Oncology. 2026;44(12):1065-1067. doi:10.1200/jco-25-03105
BibTeX
@article{Khan2026,
author = {Khan, M Raheel and Forde, Patrick M},
title = {How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {12},
pages = {1065--1067},
doi = {10.1200/jco-25-03105}
}
EUVIMED